Clinical trial NCT02819817: A Trial of Topical Aloe Vera Gel in Emergency Department Patients Presenting With Simple Traumatic Wounds
Official title: A Parallel Group Double Blind Placebo Randomised Controlled Trial (RCT) of Topical Aloe Vera Gel in Emergency Department (ED) Patients Presenting With Simple Traumatic Wounds
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: PHASE1
PHASE2
Conditions: Injuries and Wounds
Keywords: Aloe Vera, wound, healing
Lead sponsor: NHS Lothian
Sponsor class: OTHER_GOV
Collaborators: name: University of Edinburgh
First posted: 2016-06-30
Enrollment: 0
Sex: ALL
Minimum age (years): 16
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This is a double blind placebo-controlled RCT comparing the speed of healing of simple traumatic wounds with Aloe Vera gel compared to both control (Ultrasound gel) and standard care.

Detailed description: Simple traumatic wounds are a common presenting symptom to the ED affecting thousands of patients worldwide every day. Aloe Vera is a natural product that has been linked to better healing both anecdotally and in animal studies. A recent Cochrane review failed to find any human studies on acute wounds such as those seen in the ED. The aim of this study is to see whether Aloe Vera gel improves the wound healing time in these patients. We plan to enrol 270 participants presenting to the Royal Infirmary of Edinburgh ED with simple traumatic wounds into a randomised controlled trial. Participants will be assessed at baseline using the Bates-Jensen wound assessment tool. They will be then be randomized to one of three groups, and allocated to receive either Aloe Vera gel, control (Ultrasound gel) or standard care. The participants in the two gel groups will have identical packaging and the treating clinician will be unaware as to which group they are allocated. They will be asked to place the allocated substance onto the wound twice daily and cover with a supplied dressing on each occasion for 1 week. All groups will be asked to return to the ED for a repeat Bates-Jensen wound assessment, and will also be asked to record the number of days that their wound took to heal. The gel groups will have assessment of product usage. Participants will also be telephoned at 3 weeks. Primary outcome will be number of days for wound to heal. Secondary outcome will be change in Bates-Jensen wound assessment score between baseline and day 10, change in wound size between baseline and day 10 and baseline and day 21, changes in wound characteristics at day 21 as reported by participants, wound infection rate, participant satisfaction and participant compliance with treatment.

Eligibility criteria: Inclusion Criteria: Patients deemed by their treating clinician to have a simple traumatic wound will be considered for enrolment.

Exclusion Criteria:

1. Known allergy to either Aloe Vera or ultrasound gel
2. Patients under 16 year of age
3. No telephone number for follow-up
4. Patient lacking capacity
5. Patient currently using antibiotics
6. Patient having a puncture or bite wound
7. Patient having underlying tendon or bone involvement or wound overlying a joint
8. Patients with burn wounds
9. Wounds more than 24 hours old
10. Patient unable/unwilling to attend follow-up
11. Patients unable to self administer treatment.
12. Wound that treating clinician would not routinely dress e.g. facial wounds (face, ear, eyebrow, nose, lip, eyelid, scalp), mucosa and hair covered areas, or wounds that require specialist dressing
13. Self reported pregnancy
14. Patients with a known allergy to the study dressing
15. Patients currently recruited in another clinical trial
16. Patients already recruited in the ALOE Study

Primary outcomes:
measure: Number of days for wound to heal (defined as epithelial closure without discharge or scab formation)
timeFrame: Day 21 (+/- 2 days)
Secondary outcomes:
measure: Numerical change in Bates-Jensen wound assessment score between baseline and day 10 (+/- 2 days)
timeFrame: Baseline and day 10 (+/- 2 days)
measure: Size (width and height in mm) of wound at baseline, day 10 (+/- 2 days), and day 21 (+/- 2 days)
timeFrame: Baseline, day 10 (+/- 2 days) and day 21 (+/- 2 days)
measure: Characteristics (visibility of wound edges and leakage from wound) as reported by participant at day 21 (+/- 2 days)
timeFrame: Day 21 (+/- 2 days)
measure: Wound infection rate
timeFrame: Day 21 (+/- 2 days)
measure: Participant satisfaction score
timeFrame: Day 21 (+/- 2 days)
measure: Participant treatment compliance (i.e. the total weight of gel used)
timeFrame: Day 10 (+/- 2 days)
Other outcomes:
Locations:
city: Edinburgh
country: United Kingdom
facility: Royal Infirmary of Edinburgh
state: Midlothian
Study officials:
affiliation: NHS Lothian
name: Matthew J Reed, MA FRCEM MD
role: PRINCIPAL_INVESTIGATOR
References: